Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cidara Therapeutics Inc CDTX

Healthcare Biotechnology
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak... see more

Recent & Breaking News (NDAQ:CDTX)

Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara's CD73 Oncology DFC Program

GlobeNewswire February 1, 2023

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

GlobeNewswire January 25, 2023

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform

GlobeNewswire January 4, 2023

Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388

GlobeNewswire December 1, 2022

Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote "FOR" Proposed Reverse Stock Split

GlobeNewswire November 29, 2022

Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

GlobeNewswire November 28, 2022

Cidara Therapeutics to Participate in the World Antiviral Congress 2022

GlobeNewswire November 23, 2022

Cidara Therapeutics to Present at the Stifel Healthcare Conference

GlobeNewswire November 8, 2022

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022

GlobeNewswire October 17, 2022

Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma

GlobeNewswire October 4, 2022

Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

GlobeNewswire September 20, 2022

Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza

GlobeNewswire September 13, 2022

Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

GlobeNewswire September 6, 2022

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 9, 2022

Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.

GlobeNewswire July 27, 2022

Cidara Therapeutics to Host Research and Development Day

GlobeNewswire June 27, 2022

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 11, 2022

Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022

GlobeNewswire April 14, 2022

Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza

GlobeNewswire March 31, 2022